Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med.57,119–137 (2006).
  Medline CASGoogle Scholar
• 2  Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther.270,414–423 (1994).
  Medline CASGoogle Scholar
• 3  Heilmann LJ, Sheen YY, Bigelow SW, Nebert DW: Trout P450IA1: cDNA and deduced protein sequence, expression in liver, and evolutionary significance. DNA7,379–387 (1988).
  Medline CASGoogle Scholar
• 4  Liang HC, Li H, McKinnon RA et al.: Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. Proc. Natl Acad. Sci. USA93,1671–1676 (1996).
  Medline CASGoogle Scholar
• 5  Sansen S, Yano JK, Reynald RL et al.: Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem.282,14348–14355 (2007).
  Medline CASGoogle Scholar
• 6  Lewis DF: On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. Biochem. Pharmacol.60,293–306 (2000).
  Medline CASGoogle Scholar
• 7  Bertilsson L, Carrillo JA, Dahl ML et al.: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol.38,471–473 (1994).
  Medline CASGoogle Scholar
• 8  Fang J, Coutts RT, McKenna KF, Baker GB: Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch. Pharmacol.358,592–599 (1998).
  Medline CASGoogle Scholar
• 9  Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet.37,177–193 (1999).
  Medline CASGoogle Scholar
• 10  Ring BJ, Catlow J, Lindsay TJ et al.: Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther.276,658–666 (1996).
  Medline CASGoogle Scholar
• 11  Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW: Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab. Dispos.25,1298–1303 (1997).
  Medline CASGoogle Scholar
• 12  Orlando R, Piccoli P, de Martin S, Padrini R, Floreani M, Palatini P: Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin. Pharmacol. Ther.75,80–88 (2004).
  Medline CASGoogle Scholar
• 13  Granfors MT, Backman JT, Laitila J, Neuvonen PJ: Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br. J. Clin. Pharmacol.57,349–353 (2004).
  Medline CASGoogle Scholar
• 14  Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK: Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab. Dispos.23,929–934 (1995).
  Medline CASGoogle Scholar
• 15  Fontana RJ, deVries TM, Woolf TF et al.: Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer’s disease. Br. J. Clin. Pharmacol.46,221–228 (1998).
  Medline CASGoogle Scholar
• 16  Facciola G, Hidestrand M, von Bahr C, Tybring G: Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur. J. Clin. Pharmacol.56,881–888 (2001).
  Medline CASGoogle Scholar
• 17  Hartter S, Ursing C, Morita S et al.: Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin. Pharmacol. Ther.70,10–16 (2001).
  Medline CASGoogle Scholar
• 18  Yamazaki H, Shaw PM, Guengerich FP, Shimada T: Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem. Res. Toxicol.11,659–665 (1998).
  Medline CASGoogle Scholar
• 19  Zaccaro C, Sweitzer S, Pipino S et al.: Role of cytochrome P450 1A2 in bilirubin degradation studies in Cyp1a2 (-/-) mutant mice. Biochem. Pharmacol.61,843–849 (2001).
  Medline CASGoogle Scholar
• 20  Lambrecht RW, Jacobs JM, Sinclair PR, Sinclair JF: Inhibition of uroporphyrinogen decarboxylase activity. The role of cytochrome P-450-mediated uroporphyrinogen oxidation. Biochem. J.269,437–441 (1990).
  Medline CASGoogle Scholar
• 21  Eaton DL, Gallagher EP, Bammler TK, Kunze KL: Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics5,259–274 (1995).
  Medline CASGoogle Scholar
• 22  Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF: Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl Acad. Sci. USA86,7696–7700 (1989).
  Medline CASGoogle Scholar
• 23  Boobis AR, Lynch AM, Murray S et al.: CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res.54,89–94 (1994).
  Medline CASGoogle Scholar
• 24  Kim D, Guengerich FP: Cytochrome P450 activation of arylamines and heterocyclic amines. Annu. Rev. Pharmacol. Toxicol.45,27–49 (2005).
  Medline CASGoogle Scholar
• 25  Gallagher EP, Wienkers LC, Stapleton PL, Kunze KL, Eaton DL: Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res.54,101–108 (1994).
  Medline CASGoogle Scholar
• 26  Gu L, Gonzalez FJ, Kalow W, Tang BK: Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics2,73–77 (1992).
  Medline CASGoogle Scholar
• 27  Fuhr U, Rost KL, Engelhardt R et al.: Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics6,159–176 (1996).
  Medline CASGoogle Scholar
• 28  Kalow W, Tang BK: The use of caffeine for enzyme assays: a critical appraisal. Clin. Pharmacol. Ther.53,503–514 (1993).
  Medline CASGoogle Scholar
• 29  Carrillo JA, Christensen M, Ramos SI et al.: Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther. Drug Monit.22,409–417 (2000).
  Medline CASGoogle Scholar
• 30  Kalow W, Tang BK: Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin. Pharmacol. Ther.50,508–519 (1991).
  Medline CASGoogle Scholar
• 31  Sarkar MA, Hunt C, Guzelian PS, Karnes HT: Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab. Dispos.20,31–37 (1992).
  Medline CASGoogle Scholar
• 32  Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J. Pharm. Sci.87,1502–1507 (1998).
  Medline CASGoogle Scholar
• 33  Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT: Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol.48,923–936 (1994).
  Medline CASGoogle Scholar
• 34  Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA: Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics3,239–249 (1993).
  Medline CASGoogle Scholar
• 35  Vistisen K, Poulsen HE, Loft S: Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis13,1561–1568 (1992).
  Medline CASGoogle Scholar
• 36  Rasmussen BB, Brosen K: Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther. Drug Monit.18,254–262 (1996).
  Medline CASGoogle Scholar
• 37  Catteau A, Bechtel YC, Poisson N, Bechtel PR, Bonaiti-Pellie C: A population and family study of CYP1A2 using caffeine urinary metabolites. Eur. J. Clin. Pharmacol.47,423–430 (1995).
  Medline CASGoogle Scholar
• 38  Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T: Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol. Biomarkers Prev.3,413–421 (1994).
  Medline CASGoogle Scholar
• 39  Schrenk D, Brockmeier D, Morike K, Bock KW, Eichelbaum M: A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur. J. Clin. Pharmacol.53,361–367 (1998).
  Medline CASGoogle Scholar
• 40  Butler MA, Lang NP, Young JF et al.: Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics2,116–127 (1992).
  Medline CASGoogle Scholar
• 41  Ilett KF, Castleden WM, Vandongen YK, Stacey MC, Butler MA, Kadlubar FF: Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease. Clin. Pharmacol. Ther.54,317–322 (1993).
  Medline CASGoogle Scholar
• 42  Ou-Yang DS, Huang SL, Wang W et al.: Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br. J. Clin. Pharmacol.49,145–151 (2000).
  Medline CASGoogle Scholar
• 43  Landi MT, Sinha R, Lang NP, Kadlubar FF: Human cytochrome P4501A2. IARC Sci. Publ.148,173–195 (1999).
  CASGoogle Scholar
• 44  Sesardic D, Boobis AR, Edwards RJ, Davies DS: A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br. J. Clin. Pharmacol.26,363–372 (1988).
  Medline CASGoogle Scholar
• 45  Ma Q, Lu AY: CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab. Dispos.35,1009–1016 (2007).• Reviews the role of the CYP1A family in the metabolic activation of carcinogenic polycyclic aromatic amines/amides leading to toxicity and cancer.
  Medline CASGoogle Scholar
• 46  Kall MA, Clausen J: Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man. Hum. Exp. Toxicol.14,801–807 (1995).
  Medline CASGoogle Scholar
• 47  Diaz D, Fabre I, Daujat M et al.: Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology99,737–747 (1990).
  Medline CASGoogle Scholar
• 48  Carbo M, Segura J, de la Torre R, Badenas JM, Cami J: Effect of quinolones on caffeine disposition. Clin. Pharmacol. Ther.45,234–240 (1989).
  Medline CASGoogle Scholar
• 49  Abernethy DR, Todd EL: Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur. J. Clin. Pharmacol.28,425–428 (1985).
  Medline CASGoogle Scholar
• 50  Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W: Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur. J. Clin. Pharmacol.48,161–166 (1995).
  Medline CASGoogle Scholar
• 51  Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol.45,1211–1214 (1993).
  Medline CASGoogle Scholar
• 52  Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K: Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol.51,73–78 (1996).
  Medline CASGoogle Scholar
• 53  Kunze KL, Trager WF: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol.6,649–656 (1993).
  Medline CASGoogle Scholar
• 54  Chen L, Bondoc FY, Lee MJ, Hussin AH, Thomas PE, Yang CS: Caffeine induces cytochrome P4501A2: induction of CYP1A2 by tea in rats. Drug Metab. Dispos.24,529–533 (1996).
  Medline CASGoogle Scholar
• 55  Faber MS, Jetter A, Fuhr U: Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin. Pharmacol. Toxicol.97,125–134 (2005).
  Medline CASGoogle Scholar
• 56  Lofgren S, Hagbjork AL, Ekman S, Fransson-Steen R, Terelius Y: Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica34,811–834 (2004).
  Medline CASGoogle Scholar
• 57  Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM: The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol.199,193–209 (2004).
  Medline CASGoogle Scholar
• 58  Carrillo JA, Benitez J: CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br. J. Clin. Pharmacol.41,605–608 (1996).
  Medline CASGoogle Scholar
• 59  Relling MV, Lin JS, Ayers GD, Evans WE: Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin. Pharmacol. Ther.52,643–658 (1992).
  Medline CASGoogle Scholar
• 60  Bock KW, Schrenk D, Forster A et al.: The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics4,209–218 (1994).
  Medline CASGoogle Scholar
• 61  Buur-Rasmussen B, Brosen K: Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur. Neuropsychopharmacol.9,453–459 (1999).
  Medline CASGoogle Scholar
• 62  Potkin SG, Bera R, Gulasekaram B et al.: Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J. Clin. Psychiatry55(Suppl. B),133–136 (1994).
  MedlineGoogle Scholar
• 63  Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A: Influence of patient-related variables on clozapine plasma levels. Am. J. Psychiatry147,1471–1475 (1990).
  Medline CASGoogle Scholar
• 64  Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J. Clin. Psychiatry60,36–40 (1999).
  Medline CASGoogle Scholar
• 65  Tang YL, Mao P, Li FM et al.: Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br. J. Clin. Pharmacol.64,49–56 (2007).
  Medline CASGoogle Scholar
• 66  Meibohm B, Beierle I, Derendorf H: How important are gender differences in pharmacokinetics? Clin. Pharmacokinet.41,329–342 (2002).
  Medline CASGoogle Scholar
• 67  Lane JD, Steege JF, Rupp SL, Kuhn CM: Menstrual cycle effects on caffeine elimination in the human female. Eur. J. Clin. Pharmacol.43,543–546 (1992).
  Medline CASGoogle Scholar
• 68  Tsutsumi K, Kotegawa T, Matsuki S et al.: The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin. Pharmacol. Ther.70,121–125 (2001).
  Medline CASGoogle Scholar
• 69  Knutti R, Rothweiler H, Schlatter C: Effect of pregnancy on the pharmacokinetics of caffeine. Eur. J. Clin. Pharmacol.21,121–126 (1981).
  Medline CASGoogle Scholar
• 70  Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L: Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype–phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol.63,537–546 (2007).
  Medline CASGoogle Scholar
• 71  Bartoli A, Xiaodong S, Gatti G, Cipolla G, Marchiselli R, Perucca E: The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther. Drug Monit.18,586–591 (1996).
  Medline CASGoogle Scholar
• 72  Chang WH, Lin SK, Lane HY, Hu WH, Jann MW, Lin HN: Clozapine dosages and plasma drug concentrations. J. Formos. Med. Assoc.96,599–605 (1997).
  Medline CASGoogle Scholar
• 73  Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith RL: The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition. Br. J. Clin. Pharmacol.16,157–166 (1983).
  Medline CASGoogle Scholar
• 74  Shahidi NT: Acetophenetidin sensitivity. Am. J. Dis. Child.113,81–82 (1967).
  Medline CASGoogle Scholar
• 75  Miller M, Opheim KE, Raisys VA, Motulsky AG: Theophylline metabolism: variation and genetics. Clin. Pharmacol. Ther.35,170–182 (1984).
  Medline CASGoogle Scholar
• 76  Miller CA, Slusher LB, Vesell ES: Polymorphism of theophylline metabolism in man. J. Clin. Invest.75,1415–1425 (1985).
  Medline CASGoogle Scholar
• 77  Rasmussen BB, Brix TH, Kyvik KO, Brosen K: The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics12,473–478 (2002).•• Roles of genetic and environmental factors (CYP1A2) in caffeine metabolism are investigated in mono- and di-zygotic twins.
  Medline CASGoogle Scholar
• 78  Corchero J, Pimprale S, Kimura S, Gonzalez FJ: Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics11,1–6 (2001).
  Medline CASGoogle Scholar
• 79  Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S: Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol. Endocrinol.3,1399–1408 (1989).
  Medline CASGoogle Scholar
• 80  Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T: Detection of three genetic polymorphisms in the 5´-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J. Cancer Res.90,899–902 (1999).
  Medline CASGoogle Scholar
• 81  Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T: Genetic polymorphism in the 5´-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. (Tokyo)125,803–808 (1999).
  Medline CASGoogle Scholar
• 82  Sachse C, Brockmoller J, Bauer S, Roots I: Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol.47,445–449 (1999).
  Medline CASGoogle Scholar
• 83  Han XM, Ouyang DS, Chen XP et al.: Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br. J. Clin. Pharmacol.54,540–543 (2002).
  Medline CASGoogle Scholar
• 84  Nordmark A, Lundgren S, Ask B, Granath F, Rane A: The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br. J. Clin. Pharmacol.54,504–510 (2002).
  Medline CASGoogle Scholar
• 85  Aklillu E, Carrillo JA, Makonnen E et al.: Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol.64,659–669 (2003).•• Demonstrates the functional significance of the different CYP1A2 intron 1 haplotypes.
  Medline CASGoogle Scholar
• 86  Sachse C, Bhambra U, Smith G et al.: Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br. J. Clin. Pharmacol.55,68–76 (2003).•• Phenotypic consequences, frequencies and linkage disequilibria of common CYP1A2 polymorphisms are described in Caucasians.
  Medline CASGoogle Scholar
• 87  Chen X, Wang L, Zhi L et al.: The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin. Pharmacol. Ther.78,249–259 (2005).
  Medline CASGoogle Scholar
• 88  Jiang Z, Dragin N, Jorge-Nebert LF et al.: Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet. Genomics16,359–367 (2006).• Provides data from resequencing the human CYP1A1_CYP1A2 locus and attempts to correlate the CYP1A2 genotype with a metabolic phenotype.
  Medline CASGoogle Scholar
• 89  Huang JD, Guo WC, Lai MD, Guo YL, Lambert GH: Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab. Dispos.27,98–101 (1999).
  Medline CASGoogle Scholar
• 90  Chevalier D, Cauffiez C, Allorge D et al.: Five novel natural allelic variants – 951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y) – of the human CYP1A2 gene in a French Caucasian population. Hum. Mutat.17,355–356 (2001).
  MedlineGoogle Scholar
• 91  Zhou H, Josephy PD, Kim D, Guengerich FP: Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch. Biochem. Biophys.422,23–30 (2004).
  Medline CASGoogle Scholar
• 92  Allorge D, Chevalier D, Lo-Guidice JM et al.: Identification of a novel splice-site mutation in the CYP1A2 gene. Br. J. Clin. Pharmacol.56,341–344 (2003).
  Medline CASGoogle Scholar
• 93  Murayama N, Soyama A, Saito Y et al.: Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J. Pharmacol. Exp. Ther.308,300–306 (2004).
  Medline CASGoogle Scholar
• 94  Saito Y, Hanioka N, Maekawa K et al.: Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab. Dispos.33,1905–1910 (2005).
  Medline CASGoogle Scholar
• 95  Soyama A, Saito Y, Hanioka N et al.: Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab. Pharmacokinet.20,24–33 (2005).
  Medline CASGoogle Scholar
• 96  Pucci L, Geppetti A, Maggini V, Lucchesi D, Maria Rossi A, Longo V: CYP1A2 F21L and F186L polymorphisms in an Italian population sample. Drug Metab. Pharmacokinet.22,220–222 (2007).
  MedlineGoogle Scholar
• 97  Dandara C, Basvi PT, Bapiro TE, Sayi J, Hasler JA: Frequency of -163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations. Clin. Chem. Lab. Med.42,939–941 (2004).
  Medline CASGoogle Scholar
• 98  Ozdemir V, Kalow W, Okey AB et al.: Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C–>A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J. Clin. Psychopharmacol.21,603–607 (2001).•• Reports the impact of the CYP1A2 -163C>A polymorphism on treatment resistance to clozapine.
  Medline CASGoogle Scholar
• 99  Aitchison KJ, Jann MW, Zhao JH et al.: Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice. J. Psychopharmacol.14,353–359 (2000).
  Medline CASGoogle Scholar
• 100  Melkersson KI, Scordo MG, Gunes A, Dahl ML: Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J. Clin. Psychiatry68,697–704 (2007).
  Medline CASGoogle Scholar
• 101  Eap CB, Bender S, Jaquenoud Sirot E et al.: Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J. Clin. Psychopharmacol.24,214–219 (2004).
  Medline CASGoogle Scholar
• 102  Skogh E, Bengtsson F, Nordin C: Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther. Drug Monit.21,580–582 (1999).
  Medline CASGoogle Scholar
• 103  Meyer JM: Individual changes in clozapine levels after smoking cessation: results and a predictive model. J. Clin. Psychopharmacol.21,569–574 (2001).
  Medline CASGoogle Scholar
• 104  Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F: Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther. Drug Monit.24,518–526 (2002).
  Medline CASGoogle Scholar
• 105  Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J: Role of the smoking-induced cytochrome P450 (CYP) 1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J. Clin. Psychopharmacol.23,119–127 (2003).
  Medline CASGoogle Scholar
• 106  Tay JK, Tan CH, Chong SA, Tan EC: Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry31,1297–1302 (2007).
  Medline CASGoogle Scholar
• 107  Basile VS, Ozdemir V, Masellis M et al.: A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiatry5,410–417 (2000).
  Medline CASGoogle Scholar
• 108  Fu Y, Fan CH, Deng HH et al.: Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol. Sin.27,328–332 (2006).
  Medline CASGoogle Scholar
• 109  Rasmussen BB, Maenpaa J, Pelkonen O et al.: Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br. J. Clin. Pharmacol.39,151–159 (1995).
  Medline CASGoogle Scholar
• 110  Obase Y, Shimoda T, Kawano T et al.: Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin. Pharmacol. Ther.73,468–474 (2003).
  Medline CASGoogle Scholar
• 111  Brzezinski A: Melatonin in humans. N. Engl. J. Med.336,186–195 (1997).
  Medline CASGoogle Scholar
• 112  Hartter S, Korhonen T, Lundgren S et al.: Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin. Basic Clin. Pharmacol. Toxicol.99,300–304 (2006).
  MedlineGoogle Scholar
• 113  Hartter S, Grozinger M, Weigmann H, Roschke J, Hiemke C: Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin. Pharmacol. Ther.67,1–6 (2000).
  Medline CASGoogle Scholar
• 114  Ursing C, von Bahr C, Brismar K, Rojdmark S: Influence of cigarette smoking on melatonin levels in man. Eur. J. Clin. Pharmacol.61,197–201 (2005).
  Medline CASGoogle Scholar
• 115  Ursing C, Hartter S, von Bahr C, Tybring G, Bertilsson L, Rojdmark S: Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in man? J. Endocrinol. Invest.25,459–462 (2002).
  Medline CASGoogle Scholar
• 116  Chen X, Wang H, Xie W et al.: Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case–control study in a high-risk region of China. Pharmacogenet. Genomics16,219–227 (2006).
  Medline CASGoogle Scholar
• 117  Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E: Influence of the genetic polymorphism in the 5´-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat. Res.587,59–66 (2005).
  Medline CASGoogle Scholar
• 118  Pavanello S, B’Chir F, Pulliero A et al.: Interaction between CYP1A2 -T2467DELT polymorphism and smoking in adenocarcinoma and squamous cell carcinoma of the lung. Lung Cancer57,266–272 (2007).
  MedlineGoogle Scholar
• 119  Osawa Y, Osawa KK, Miyaishi A et al.: NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac. J. Cancer Prev.8,103–108 (2007).
  MedlineGoogle Scholar
• 120  Bae SY, Choi SK, Kim KR et al.: Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci.97,774–779 (2006).
  Medline CASGoogle Scholar
• 121  Agudo A, Sala N, Pera G et al.: Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol. Biomarkers Prev.15,2427–2434 (2006).
  Medline CASGoogle Scholar
• 122  Li D, Jiao L, Li Y et al.: Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis27,103–111 (2006).
  MedlineGoogle Scholar
• 123  Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV: Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis18,207–214 (1997).
  Medline CASGoogle Scholar
• 124  Lurie G, Maskarinec G, Kaaks R, Stanczyk FZ, le Marchand L: Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol. Biomarkers Prev.14,1521–1527 (2005).
  Medline CASGoogle Scholar
• 125  le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR: Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev.14,1998–2003 (2005).
  Medline CASGoogle Scholar
• 126  Mikhailova ON, Gulyaeva LF, Prudnikov AV, Gerasimov AV, Krasilnikov SE: Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics J.6,189–193 (2006).
  Medline CASGoogle Scholar
• 127  Nichols RC, Cooper S, Trask HW et al.: Uroporphyrin accumulation in hepatoma cells expressing human or mouse CYP1A2: relation to the role of CYP1A2 in human porphyria cutanea tarda. Biochem. Pharmacol.65,545–550 (2003).
  Medline CASGoogle Scholar
• 128  Sinclair PR, Gorman N, Tsyrlov IB, Fuhr U, Walton HS, Sinclair JF: Uroporphyrinogen oxidation catalyzed by human cytochromes P450. Drug Metab. Dispos.26,1019–1025 (1998).
  Medline CASGoogle Scholar
• 129  Sinclair PR, Gorman N, Walton HS et al.: CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol. Appl. Pharmacol.162,60–67 (2000).
  Medline CASGoogle Scholar
• 130  Smith AG, Clothier B, Carthew P et al.: Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol.173,89–98 (2001).
  Medline CASGoogle Scholar
• 131  Christiansen L, Bygum A, Jensen A et al.: Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum. Genet.107,612–614 (2000).
  Medline CASGoogle Scholar
• 132  Signorello LB, Nordmark A, Granath F et al.: Caffeine metabolism and the risk of spontaneous abortion of normal karyotype fetuses. Obstet. Gynecol.98,1059–1066 (2001).
  Medline CASGoogle Scholar
• 133  Grosso LM, Triche EW, Belanger K, Benowitz NL, Holford TR, Bracken MB: Caffeine metabolites in umbilical cord blood, cytochrome P-450 1A2 activity, and intrauterine growth restriction. Am. J. Epidemiol.163,1035–1041 (2006).
  MedlineGoogle Scholar
• 134  Sata F, Yamada H, Suzuki K et al.: Caffeine intake, CYP1A2 polymorphism and the risk of recurrent pregnancy loss. Mol. Hum. Reprod.11,357–360 (2005).
  Medline CASGoogle Scholar
• 135  Smith AG, Davies R, Dalton TP et al.: Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics111,45–51 (2003).•• Demonstrates changes in the expressions of genes involved in cell-cycle control, insulin action, lipogenesis, fatty acid and cholesterol biosynthetic pathways are shown in CYP1A2-knockout mice.
  Medline CASGoogle Scholar
• 136  Hamdy SI, Hiratsuka M, Narahara K et al.: Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br. J. Clin. Pharmacol.55,321–324 (2003).
  Medline CASGoogle Scholar
• 201  Drugs metabolized by CYPs http://medicine.iupui.edu/flockhart/table.htm• List of drugs that are metabolized by a specific CYP isoform, and published inhibitors, inducers and genetic influences on that isoform.
  Google Scholar
• 202  CYP1A2 allele nomenclature www.cypalleles.ki.se/cyp1a2.htm
  Google Scholar
• 203  International HapMap Project: CYP1A2 allele nomenclature www.hapmap.org/
  Google Scholar